DCGI Classifies 135 Ophthalmology Related Medical Devices Under MD Rules

New Delhi : The Drugs Controller General (India) has classified 135 medical devices related to ophthalmology under the provisions of Medical Devices Rules, 2017. In another notice, it has also classified 51 medical devices pertaining to respiratory treatments under the provisions of Medical Devices Rules, 2017, the rule formed to regulate them with respect to the import, manufacture, sale and distribution, and clinical investigation.

The drug regulator listed ophthalmology-related medical devices including automated lens meter (dioptometer), bagolini lens, blepharoplasty scissors, contact lens including coloured contact lens, corneal marker, corneal scissors, corneal shield, diagnostic condensing lens, donor cornea container, euthyscope, eye cup, eye muscle clamp, eye pad, eye spud, eyelid clamp, among others.

The DCGI, in in another notice, listed the medical devices including cerebral oximeter, bulk oxygen concentration system, cough long-term ambulatory recording system, dry powder inhaler, foetal pulse oximeter, oxygen concentrator, gas pipeline/supply system air compressor, hypopnea sensor and alarm, infant apnoea monitor, manual chest percussion, nitrogen monoxide analyser, steam inhaler, stress test treadmill, therapeutic positive pressure breathing ventilator, thoracic suction pump, among others under the Medical Devices Rules.

General intended use given against each of the devices is for guidance to the applicants intended to furnish application of import or manufacture of medical devices under the provisions of Medical Devices Rules, 2017. However, a device may have specific intended use as specified by its manufacturer.

The drug regulator has earlier classified 112 medical devices pertaining to anaesthesiology and around 208 medical devices in various categories including rehabilitation, physical support, dermatology and plastic surgery and interventional radiology and another 80 in vitro diagnostic medical devices including analysers, instruments and softwares, from mid July, 2021.

  • Related Posts

    • Pharma
    • April 11, 2025
    • 96 views
    Aurobindo Pharma shares jump 4% as arm completes phase1 trial for bone drug

    Aurobindo Pharma shares jumped 5 per cent on Friday, April 11, 2025, logging an intraday high at ₹1,110 per share on BSE. The stock rallied after the company’s subsidiary, CuraTeQ…

    • Pharma
    • April 11, 2025
    • 84 views
    ‘Pharma companies need to look beyond US market’

    HYDERABAD:  With the Trump administration’s flip-flops on tariffs giving the Indian pharma industry a headache, experts feel it’s time the sector looked at an ‘America plus’ strategy to reduce heavy…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Aurobindo Pharma shares jump 4% as arm completes phase1 trial for bone drug

    Aurobindo Pharma shares jump 4% as arm completes phase1 trial for bone drug

    ‘Pharma companies need to look beyond US market’

    ‘Pharma companies need to look beyond US market’

    HC upholds validity of Bihar pharmacist rules

    HC upholds validity of Bihar pharmacist rules

    CAHOCON 2025 marks Highest Point in Quest for Culture of Patient Safety

    CAHOCON 2025 marks Highest Point in Quest for Culture of Patient Safety